You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrichlormethiazide
Accession NumberDB01021  (APRD00031)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Structure
Thumb
Synonyms
Naqua
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnistadinNot Available
CarvacronNot Available
Diu-HydrinNot Available
DiureseNot Available
FluitranNot Available
KubacronNot Available
MetahydrinNot Available
NaquaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ58C92TUN0
CAS number133-67-5
WeightAverage: 380.656
Monoisotopic: 378.90218026
Chemical FormulaC8H8Cl3N3O4S2
InChI KeyInChIKey=LMJSLTNSBFUCMU-UHFFFAOYSA-N
InChI
InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
IUPAC Name
6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of oedema (including that associated with heart failure) and hypertension.
PharmacodynamicsTrichloromethiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Trichloromethiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomer-ulonephritis, and chronic renal failure. Trichloromethiazide is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Like other thiazides, Trichloromethiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionTrichlormethiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, Trichloromethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Trichloromethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Trichloromethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral Rat LD50 = 5600 mg/kg, oral Mouse LD50 = 2600 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Trichlormethiazide Action PathwayDrug actionSMP00121
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9356
Blood Brain Barrier-0.9431
Caco-2 permeable-0.7869
P-glycoprotein substrateNon-substrate0.6958
P-glycoprotein inhibitor INon-inhibitor0.8804
P-glycoprotein inhibitor IINon-inhibitor0.9432
Renal organic cation transporterNon-inhibitor0.8959
CYP450 2C9 substrateNon-substrate0.7173
CYP450 2D6 substrateNon-substrate0.8454
CYP450 3A4 substrateNon-substrate0.6828
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9454
CYP450 2D6 inhibitorNon-inhibitor0.9582
CYP450 2C19 inhibitorNon-inhibitor0.9611
CYP450 3A4 inhibitorNon-inhibitor0.9325
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9502
Ames testNon AMES toxic0.9209
CarcinogenicityNon-carcinogens0.844
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8282 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9721
hERG inhibition (predictor II)Non-inhibitor0.9276
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Schering corp sub schering plough corp
  • Lannett co inc
  • Mm mast and co
  • Impax laboratories inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Tg united labs llc
  • Watson laboratories inc
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Trichlormethiazide powder15.0USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 dec °CPhysProp
water solubility800 mg/L (at 25 °C)MERCK (1989)
logP0.62SANGSTER (1994)
logS-2.68ADME Research, USCD
pKa8.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.415 mg/mLALOGPS
logP0.86ALOGPS
logP0.97ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.32ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.44 m3·mol-1ChemAxon
Polarizability31.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.06 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC03AA06C03AB06C03EA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Trichlormethiazide.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Trichlormethiazide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Trichlormethiazide.
AcebutololTrichlormethiazide may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Aceclofenac.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Trichlormethiazide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Trichlormethiazide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Trichlormethiazide.
AldosteroneAldosterone may increase the hypokalemic activities of Trichlormethiazide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trichlormethiazide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Trichlormethiazide.
AliskirenTrichlormethiazide may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Trichlormethiazide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Trichlormethiazide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trichlormethiazide.
AlprenololAlprenolol may increase the hypotensive activities of Trichlormethiazide.
AmbrisentanTrichlormethiazide may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Trichlormethiazide.
AmifostineTrichlormethiazide may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Trichlormethiazide.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
AmoxapineAmoxapine may increase the hyponatremic activities of Trichlormethiazide.
Anisotropine MethylbromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Antipyrine.
ApremilastThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Trichlormethiazide.
ArformoterolArformoterol may increase the hypokalemic activities of Trichlormethiazide.
AtenololAtenolol may increase the hypotensive activities of Trichlormethiazide.
Atracurium besylateThe serum concentration of Trichlormethiazide can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azelastine.
BalsalazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Trichlormethiazide.
BarbitalBarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Trichlormethiazide.
BenactyzineThe serum concentration of Trichlormethiazide can be increased when it is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Trichlormethiazide.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Trichlormethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Trichlormethiazide.
BenoxaprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Benzatropine.
BepridilTrichlormethiazide may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Trichlormethiazide.
BetaxololBetaxolol may increase the hypotensive activities of Trichlormethiazide.
BethanidineBethanidine may increase the hypotensive activities of Trichlormethiazide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Trichlormethiazide.
BimatoprostBimatoprost may increase the hypotensive activities of Trichlormethiazide.
BiperidenThe serum concentration of Trichlormethiazide can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Trichlormethiazide.
BosentanBosentan may increase the hypotensive activities of Trichlormethiazide.
BretyliumTrichlormethiazide may increase the hypotensive activities of Bretylium.
BrimonidineTrichlormethiazide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Trichlormethiazide.
BromfenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Trichlormethiazide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Trichlormethiazide.
BupranololTrichlormethiazide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trichlormethiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trichlormethiazide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.
CandesartanCandesartan may increase the hypotensive activities of Trichlormethiazide.
CandoxatrilCandoxatril may increase the hypotensive activities of Trichlormethiazide.
CaptoprilTrichlormethiazide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trichlormethiazide.
CaroxazoneCaroxazone may increase the hypotensive activities of Trichlormethiazide.
CarprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Trichlormethiazide.
CarvedilolTrichlormethiazide may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Trichlormethiazide.
CelecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Celecoxib.
CeliprololTrichlormethiazide may increase the hypotensive activities of Celiprolol.
ChloroquineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Trichlormethiazide.
ChlorphenoxamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trichlormethiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Trichlormethiazide.
CholestyramineCholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Trichlormethiazide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Trichlormethiazide.
CilazaprilTrichlormethiazide may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Trichlormethiazide.
ClenbuterolClenbuterol may increase the hypokalemic activities of Trichlormethiazide.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Trichlormethiazide.
ClocortoloneClocortolone may increase the hypokalemic activities of Trichlormethiazide.
ClomipramineClomipramine may increase the hyponatremic activities of Trichlormethiazide.
ClonidineClonidine may increase the hypotensive activities of Trichlormethiazide.
ClonixinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trichlormethiazide.
ColesevelamColesevelam can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Trichlormethiazide.
CryptenamineCryptenamine may increase the hypotensive activities of Trichlormethiazide.
CyclopentolateThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclophosphamide.
CyclothiazideCyclothiazide may increase the hypotensive activities of Trichlormethiazide.
D-LimoneneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with D-Limonene.
DapoxetineDapoxetine may increase the hyponatremic activities of Trichlormethiazide.
DarifenacinThe serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin.
DebrisoquinTrichlormethiazide may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Trichlormethiazide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Trichlormethiazide.
DeserpidineTrichlormethiazide may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside.
DesloratadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Trichlormethiazide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Trichlormethiazide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Trichlormethiazide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Trichlormethiazide.
DexetimideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Trichlormethiazide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trichlormethiazide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trichlormethiazide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trichlormethiazide.
DiazoxideDiazoxide may increase the hypotensive activities of Trichlormethiazide.
DiazoxideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diclofenac.
DicyclomineThe serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Trichlormethiazide.
DiflunisalThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Trichlormethiazide.
DifluprednateDifluprednate may increase the hypokalemic activities of Trichlormethiazide.
DigitoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichlormethiazide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trichlormethiazide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trichlormethiazide.
DiltiazemDiltiazem may increase the hypotensive activities of Trichlormethiazide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trichlormethiazide.
DipivefrinDipivefrin may increase the hypokalemic activities of Trichlormethiazide.
DobutamineDobutamine may increase the hypokalemic activities of Trichlormethiazide.
DofetilideTrichlormethiazide may increase the QTc-prolonging activities of Dofetilide.
DorzolamideDorzolamide may increase the hypotensive activities of Trichlormethiazide.
DoxazosinDoxazosin may increase the hypotensive activities of Trichlormethiazide.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Trichlormethiazide.
DroxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Trichlormethiazide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Trichlormethiazide.
EfonidipineTrichlormethiazide may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Trichlormethiazide.
EnalaprilEnalapril may increase the hypotensive activities of Trichlormethiazide.
EnalaprilatTrichlormethiazide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Trichlormethiazide.
EpinephrineEpinephrine may increase the hypokalemic activities of Trichlormethiazide.
EpirizoleThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Epirizole.
EpoprostenolTrichlormethiazide may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Trichlormethiazide.
EquileninEquilenin may increase the hypokalemic activities of Trichlormethiazide.
EquilinEquilin may increase the hypokalemic activities of Trichlormethiazide.
EscitalopramEscitalopram may increase the hyponatremic activities of Trichlormethiazide.
EstroneEstrone may increase the hypokalemic activities of Trichlormethiazide.
EtanerceptThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Trichlormethiazide.
EthopropazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trichlormethiazide.
EtodolacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Trichlormethiazide.
EtoricoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trichlormethiazide.
Evening primrose oilThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Trichlormethiazide.
exisulindThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with exisulind.
FelodipineTrichlormethiazide may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Trichlormethiazide.
FenoldopamFenoldopam may increase the hypotensive activities of Trichlormethiazide.
FenoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Trichlormethiazide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichlormethiazide.
FesoterodineThe serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Trichlormethiazide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Trichlormethiazide.
FlunisolideFlunisolide may increase the hypokalemic activities of Trichlormethiazide.
FlunixinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Trichlormethiazide.
FluocinonideFluocinonide may increase the hypokalemic activities of Trichlormethiazide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Trichlormethiazide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Trichlormethiazide.
FluoxetineFluoxetine may increase the hyponatremic activities of Trichlormethiazide.
FluprednideneFluprednidene may increase the hypokalemic activities of Trichlormethiazide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Trichlormethiazide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Trichlormethiazide.
FlurbiprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Trichlormethiazide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Trichlormethiazide.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Trichlormethiazide.
FormoterolFormoterol may increase the hypokalemic activities of Trichlormethiazide.
FosinoprilFosinopril may increase the hypotensive activities of Trichlormethiazide.
FurazolidoneFurazolidone may increase the hypotensive activities of Trichlormethiazide.
Gallamine TriethiodideThe serum concentration of Trichlormethiazide can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Trichlormethiazide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Trichlormethiazide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Trichlormethiazide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Trichlormethiazide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Trichlormethiazide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Trichlormethiazide.
GlycopyrroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Glycopyrronium.
GuanabenzGuanabenz may increase the hypotensive activities of Trichlormethiazide.
GuanadrelGuanadrel may increase the hypotensive activities of Trichlormethiazide.
GuanethidineTrichlormethiazide may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Trichlormethiazide.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trichlormethiazide.
HexamethoniumTrichlormethiazide may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
HMPL-004The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Trichlormethiazide.
HydralazineTrichlormethiazide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Trichlormethiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Trichlormethiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Trichlormethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide.
HyoscyamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Trichlormethiazide.
IndacaterolIndacaterol may increase the hypokalemic activities of Trichlormethiazide.
IndalpineIndalpine may increase the hyponatremic activities of Trichlormethiazide.
IndapamideIndapamide may increase the hypotensive activities of Trichlormethiazide.
IndenololTrichlormethiazide may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indoprofen.
IndoraminTrichlormethiazide may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Trichlormethiazide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Trichlormethiazide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Trichlormethiazide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Trichlormethiazide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Trichlormethiazide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Trichlormethiazide.
Ipratropium bromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Trichlormethiazide.
IproniazidIproniazid may increase the hypotensive activities of Trichlormethiazide.
IrbesartanTrichlormethiazide may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Trichlormethiazide.
IsoetarineIsoetarine may increase the hypokalemic activities of Trichlormethiazide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Trichlormethiazide.
IsoxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Trichlormethiazide.
IvabradineTrichlormethiazide may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trichlormethiazide.
KetoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Trichlormethiazide.
LacidipineTrichlormethiazide may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Trichlormethiazide.
LeflunomideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Trichlormethiazide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trichlormethiazide.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Trichlormethiazide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trichlormethiazide.
LicoriceLicorice may increase the hypokalemic activities of Trichlormethiazide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Trichlormethiazide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Trichlormethiazide.
LisinoprilLisinopril may increase the hypotensive activities of Trichlormethiazide.
LithiumTrichlormethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Trichlormethiazide.
LofexidineTrichlormethiazide may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Trichlormethiazide.
LoxoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Trichlormethiazide.
LumiracoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lumiracoxib.
MacitentanTrichlormethiazide may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Magnesium salicylate.
ManidipineTrichlormethiazide may increase the hypotensive activities of Manidipine.
MasoprocolThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Trichlormethiazide.
MecamylamineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Trichlormethiazide.
Meclofenamic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Trichlormethiazide.
Mefenamic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Trichlormethiazide.
MeloxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trichlormethiazide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trichlormethiazide.
MethanthelineThe serum concentration of Trichlormethiazide can be increased when it is combined with Methantheline.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Trichlormethiazide.
MethyldopaMethyldopa may increase the hypotensive activities of Trichlormethiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Trichlormethiazide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Trichlormethiazide.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Trichlormethiazide.
MetipranololTrichlormethiazide may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Trichlormethiazide can be increased when it is combined with Metixene.
MetolazoneMetolazone may increase the hypotensive activities of Trichlormethiazide.
MetoprololMetoprolol may increase the hypotensive activities of Trichlormethiazide.
MibefradilTrichlormethiazide may increase the hypotensive activities of Mibefradil.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Trichlormethiazide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Trichlormethiazide.
MilnacipranMilnacipran may increase the hyponatremic activities of Trichlormethiazide.
MinaprineMinaprine may increase the hypotensive activities of Trichlormethiazide.
MinoxidilMinoxidil may increase the hypotensive activities of Trichlormethiazide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Trichlormethiazide.
MoclobemideMoclobemide may increase the hypotensive activities of Trichlormethiazide.
MoexiprilMoexipril may increase the hypotensive activities of Trichlormethiazide.
MolsidomineMolsidomine may increase the hypotensive activities of Trichlormethiazide.
MometasoneMometasone may increase the hypokalemic activities of Trichlormethiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trichlormethiazide.
MoxonidineTrichlormethiazide may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Trichlormethiazide can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.
NadololTrichlormethiazide may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trichlormethiazide.
NaproxenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Trichlormethiazide.
NCX 4016The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with NCX 4016.
NebivololTrichlormethiazide may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Trichlormethiazide.
NicardipineNicardipine may increase the hypotensive activities of Trichlormethiazide.
NicorandilTrichlormethiazide may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Niflumic Acid.
NiguldipineTrichlormethiazide may increase the hypotensive activities of Niguldipine.
NilvadipineTrichlormethiazide may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Trichlormethiazide.
NisoldipineNisoldipine may increase the hypotensive activities of Trichlormethiazide.
NitrendipineTrichlormethiazide may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Trichlormethiazide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Trichlormethiazide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Trichlormethiazide.
NVA237The serum concentration of Trichlormethiazide can be increased when it is combined with NVA237.
ObinutuzumabTrichlormethiazide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Trichlormethiazide.
OlanzapineOlanzapine may increase the hyponatremic activities of Trichlormethiazide.
OlmesartanOlmesartan may increase the hypotensive activities of Trichlormethiazide.
OlodaterolOlodaterol may increase the hypokalemic activities of Trichlormethiazide.
OlopatadineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Trichlormethiazide.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Trichlormethiazide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Trichlormethiazide.
OrgoteinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Oxcarbazepine.
OxprenololTrichlormethiazide may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichlormethiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trichlormethiazide.
OxyphenbutazoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Pancuronium.
ParamethasoneParamethasone may increase the hypokalemic activities of Trichlormethiazide.
ParecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Parecoxib.
PargylineTrichlormethiazide may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Trichlormethiazide.
PenbutololTrichlormethiazide may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
PentoliniumTrichlormethiazide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Trichlormethiazide.
PerindoprilPerindopril may increase the hypotensive activities of Trichlormethiazide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trichlormethiazide.
PhenelzinePhenelzine may increase the hypotensive activities of Trichlormethiazide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Trichlormethiazide.
PheniprazinePheniprazine may increase the hypotensive activities of Trichlormethiazide.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Trichlormethiazide.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Trichlormethiazide.
PhentolaminePhentolamine may increase the hypotensive activities of Trichlormethiazide.
PhenylbutazoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Trichlormethiazide.
PimecrolimusThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pimecrolimus.
PinacidilTrichlormethiazide may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Trichlormethiazide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Trichlormethiazide.
PipecuroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Trichlormethiazide.
PirenzepineThe serum concentration of Trichlormethiazide can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Trichlormethiazide.
PiroxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Trichlormethiazide.
PolythiazideTrichlormethiazide may increase the hypotensive activities of Polythiazide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Trichlormethiazide.
PrazosinPrazosin may increase the hypotensive activities of Trichlormethiazide.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Trichlormethiazide.
PrednisolonePrednisolone may increase the hypokalemic activities of Trichlormethiazide.
PrednisonePrednisone may increase the hypokalemic activities of Trichlormethiazide.
PregnenolonePregnenolone may increase the hypokalemic activities of Trichlormethiazide.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Trichlormethiazide.
ProcaterolProcaterol may increase the hypokalemic activities of Trichlormethiazide.
ProcyclidineThe serum concentration of Trichlormethiazide can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Trichlormethiazide can be increased when it is combined with Propantheline.
PropranololPropranolol may increase the hypotensive activities of Trichlormethiazide.
PTC299The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with PTC299.
QuinaprilQuinapril may increase the hypotensive activities of Trichlormethiazide.
QuinidineThe serum concentration of Trichlormethiazide can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Trichlormethiazide.
RamiprilRamipril may increase the hypotensive activities of Trichlormethiazide.
RasagilineRasagiline may increase the hypotensive activities of Trichlormethiazide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichlormethiazide.
RemikirenRemikiren may increase the hypotensive activities of Trichlormethiazide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Trichlormethiazide.
RescinnamineTrichlormethiazide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Trichlormethiazide.
ResveratrolThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Trichlormethiazide.
RiociguatTrichlormethiazide may increase the hypotensive activities of Riociguat.
RitodrineRitodrine may increase the hypokalemic activities of Trichlormethiazide.
RituximabTrichlormethiazide may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Trichlormethiazide.
SafrazineSafrazine may increase the hypotensive activities of Trichlormethiazide.
SalbutamolSalbutamol may increase the hypokalemic activities of Trichlormethiazide.
SalicylamideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Trichlormethiazide.
SalsalateThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salsalate.
SaprisartanTrichlormethiazide may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Trichlormethiazide.
ScopolamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
SelegilineSelegiline may increase the hypotensive activities of Trichlormethiazide.
SelexipagTrichlormethiazide may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Trichlormethiazide.
SildenafilSildenafil may increase the antihypertensive activities of Trichlormethiazide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Trichlormethiazide.
SitaxentanTrichlormethiazide may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Trichlormethiazide can be increased when it is combined with Solifenacin.
SpiraprilTrichlormethiazide may increase the hypotensive activities of Spirapril.
SRT501The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.
SulfasalazineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Trichlormethiazide.
SulpirideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Trichlormethiazide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trichlormethiazide.
TelmisartanTelmisartan may increase the hypotensive activities of Trichlormethiazide.
TemocaprilTrichlormethiazide may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tepoxalin.
TerbutalineTerbutaline may increase the hypokalemic activities of Trichlormethiazide.
TeriflunomideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Teriflunomide.
TerlipressinTrichlormethiazide may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Trichlormethiazide.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Trichlormethiazide.
Tiaprofenic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tiaprofenic acid.
TiboloneTrichlormethiazide may increase the hypotensive activities of Tibolone.
TicrynafenTrichlormethiazide may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Trichlormethiazide.
TiotropiumThe serum concentration of Trichlormethiazide can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Trichlormethiazide.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Trichlormethiazide.
TolazolineTolazoline may increase the hypotensive activities of Trichlormethiazide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Trichlormethiazide.
Tolfenamic AcidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Trichlormethiazide.
TolterodineThe serum concentration of Trichlormethiazide can be increased when it is combined with Tolterodine.
TopiramateTrichlormethiazide may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Trichlormethiazide.
ToremifeneTrichlormethiazide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trichlormethiazide.
TrandolaprilTrandolapril may increase the hypotensive activities of Trichlormethiazide.
TranilastThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trichlormethiazide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Trichlormethiazide.
TravoprostTravoprost may increase the hypotensive activities of Trichlormethiazide.
TrazodoneTrazodone may increase the hyponatremic activities of Trichlormethiazide.
TreprostinilTreprostinil may increase the hypotensive activities of Trichlormethiazide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Trichlormethiazide can be increased when it is combined with Trihexyphenidyl.
TrimazosinTrichlormethiazide may increase the hypotensive activities of Trimazosin.
TrimethaphanTrichlormethiazide may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Trichlormethiazide.
TropicamideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Trichlormethiazide can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Trichlormethiazide can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Trichlormethiazide.
UmeclidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Umeclidinium.
UnoprostoneTrichlormethiazide may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Trichlormethiazide.
VardenafilVardenafil may increase the antihypertensive activities of Trichlormethiazide.
VecuroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Vecuronium.
VilanterolVilanterol may increase the hypokalemic activities of Trichlormethiazide.
VilazodoneVilazodone may increase the hyponatremic activities of Trichlormethiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Trichlormethiazide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Trichlormethiazide.
VortioxetineVortioxetine may increase the hyponatremic activities of Trichlormethiazide.
XylometazolineTrichlormethiazide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Trichlormethiazide.
ZaltoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Trichlormethiazide.
ZomepiracThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Li J, Wang DH: Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72. [PubMed:17414671 ]
  2. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H: Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9. Epub 2003 Nov 10. [PubMed:14610216 ]
  3. Smith SM: Thiazide diuretics. N Engl J Med. 2010 Feb 18;362(7):659-60; author reply 660. [PubMed:20187262 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Takahashi N, Kondo Y, Fujiwara I, Ito O, Igarashi Y, Abe K: Characterization of Na+ transport across the cell membranes of the ascending thin limb of Henle's loop. Kidney Int. 1995 Mar;47(3):789-94. [PubMed:7752578 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thiopurine s-methyltransferase activity
Specific Function:
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:
TPMT
Uniprot ID:
P51580
Molecular Weight:
28180.09 Da
References
  1. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393-6. [PubMed:8866635 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23